^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAT1308

    i
    Other names: BAT1308, BAT-1308, BAT 1308
    Associations

    News

    Trials
    Company:
    Bio-Thera Solutions
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    21d
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Bio-Thera Solutions | N=204 --> 112
    Enrollment change • Metastases
    |
    BAT8008 • BAT1308
    1m
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=204, Recruiting, Bio-Thera Solutions | N=50 --> 204
    Enrollment change • Metastases
    |
    BAT8008 • BAT1308
    1m
    BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Nov 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • Metastases
    |
    carboplatin • paclitaxel • BAT1308
    6ms
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BAT8008 • BAT1308
    8ms
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Bio-Thera Solutions
    New P1/2 trial
    |
    BAT8008 • BAT1308
    8ms
    BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer (clinicaltrials.gov)
    P2/3, N=140, Recruiting, Bio-Thera Solutions
    New P2/3 trial • Combination therapy • Mismatch repair • Metastases
    |
    carboplatin • paclitaxel • BAT1308
    8ms
    Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients (clinicaltrials.gov)
    P1, N=210, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BAT1308
    11ms
    Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients (clinicaltrials.gov)
    P1, N=210, Not yet recruiting, Bio-Thera Solutions
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    BAT1308
    almost1year
    Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients (clinicaltrials.gov)
    P1, N=210, Not yet recruiting, Bio-Thera Solutions
    New P1 trial • Metastases
    |
    BAT1308
    1year
    BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer (clinicaltrials.gov)
    P2/3, N=526, Not yet recruiting, Bio-Thera Solutions
    New P2/3 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Avzivi (bevacizumab-tnjn) • BAT1308
    1year
    Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients (clinicaltrials.gov)
    P1, N=13, Terminated, Bio-Thera Solutions | N=29 --> 13 | Trial completion date: Jun 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2023; Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    BAT1308
    almost3years
    Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=148, Recruiting, Bio-Thera Solutions
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    BAT1308